Healthcare & Life Sciences

The team has an established reputation for independence and for identifying assets that offer exciting therapeutics potential or where services & products (or management’s execution) mean that companies or technologies stand out from the peer group and improve care outcomes.

We have a high level of technical expertise – from bench science to the complexities of the NHS – and an ability to explain complex topics from across all the sub-sectors.

Miles Dixon joined Peel Hunt in 2017 after several years working for FTI Consulting’s Corporate Finance & Restructuring vertical where he specialised in operational turnaround for strained healthcare organisations. Prior to that he worked at Serco Group, initially in business development for their healthcare interests but latterly in a wider strategic capacity for their Local & Regional Government division across UK&E. Miles also has a number of years’ experience in life scientific research, completing postdoctoral positions in Cell Signalling & Immunology – working with both Academia and Pharma in a novel collaboration – after a bachelors in Biochemistry, a masters in Cell Biology and a doctorate in Molecular Physiology. Miles is a Fellow of the Royal Society of Biology.


No. of companies covered
No. of Corporate Clients

Biotech – The Cutting Edge

Armadillos & regenerative medicine | US legislation
In our readings from last week, we highlight leprosy, armadillos, a new potential mechanism for Alzheimer’s and delve into US legislation changes that are causing a few discussions on the Healthcare desk, and could affect the Biopharma landscape in ten+ years.


Miles Dixon

Research analyst